These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. Minami Y; Sasaki T; Arai Y; Kurisu Y; Hisamichi S J Rheumatol; 2003 Apr; 30(4):747-54. PubMed ID: 12672194 [TBL] [Abstract][Full Text] [Related]
3. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383 [TBL] [Abstract][Full Text] [Related]
4. [Hyperprolactinemia in systemic lupus erythematosus. A prospective study of 38 cases]. Smiti Khanfir M; Ben Ghorbel I; Feki M; Lamloum M; Mebazaa A; Miled M; Houman MH Tunis Med; 2004 Jun; 82(6):512-5. PubMed ID: 15517949 [TBL] [Abstract][Full Text] [Related]
5. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356 [TBL] [Abstract][Full Text] [Related]
7. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265 [TBL] [Abstract][Full Text] [Related]
8. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. Abrahamowicz M; Fortin PR; du Berger R; Nayak V; Neville C; Liang MH J Rheumatol; 1998 Feb; 25(2):277-84. PubMed ID: 9489819 [TBL] [Abstract][Full Text] [Related]
9. [Soluble interleukin 2 receptor as activity parameter in serum of systemic and discoid lupus erythematosus]. Blum C; Zillikens D; Tony HP; Hartmann AA; Burg G Hautarzt; 1993 May; 44(5):290-5. PubMed ID: 8320115 [TBL] [Abstract][Full Text] [Related]
10. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Bertoli AM; Alarcón GS; Calvo-Alén J; Fernández M; Vilá LM; Reveille JD; Arthritis Rheum; 2006 May; 54(5):1580-7. PubMed ID: 16645994 [TBL] [Abstract][Full Text] [Related]
11. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement. Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989 [TBL] [Abstract][Full Text] [Related]
12. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629 [TBL] [Abstract][Full Text] [Related]
14. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Ruperto N; Ravelli A; Cuttica R; Espada G; Ozen S; Porras O; Sztajnbok F; Falcini F; Kasapcopur O; Venning H; Bica B; Merino R; Coto C; Ros J; Susic G; Gamir ML; Minden K; See Y; Uziel Y; Mukamel M; Riley P; Zulian F; Olivieri AN; Cimaz R; Girschick H; Rumba I; Cavuto S; Pistorio A; Lovell DJ; Martini A; ; Arthritis Rheum; 2005 Sep; 52(9):2854-64. PubMed ID: 16142708 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. Ward MM; Marx AS; Barry NN J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805 [TBL] [Abstract][Full Text] [Related]
16. Useful laboratory measurements in the management of systemic lupus erythematosus. Morrow WJ; Isenberg DA; Todd-Pokropek A; Parry HF; Snaith ML Q J Med; 1982; 51(202):125-38. PubMed ID: 6981121 [TBL] [Abstract][Full Text] [Related]
17. Review of classification criteria for systemic lupus erythematosus. Petri M Rheum Dis Clin North Am; 2005 May; 31(2):245-54, vi. PubMed ID: 15922144 [TBL] [Abstract][Full Text] [Related]
18. An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus. Milligan SE; Hom DL; Ballou SP; Persse LJ; Svilar GM; Coulton CJ J Rheumatol; 1993 Jun; 20(6):972-6. PubMed ID: 8350333 [TBL] [Abstract][Full Text] [Related]
19. Defining lupus cases for clinical studies: the Boston weighted criteria for the classification of systemic lupus erythematosus. Costenbader KH; Karlson EW; Mandl LA J Rheumatol; 2002 Dec; 29(12):2545-50. PubMed ID: 12465149 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of preliminary criteria for classification of lupus systemic erythematosus suggested by the American Rheumatologic Association in the light of our 50 cases of said disease]. Maldykowa H; Chwalińska-Sadowska H Reumatologia; 1974; 12(3):261-6. PubMed ID: 4409504 [No Abstract] [Full Text] [Related] [Next] [New Search]